Canaccord Genuity Maintains a 'Buy' on GenMark Diagnostics (GNMK); Q2 Preview: Expecting Really Good Numbers
Tweet Send to a FriendGet Alerts GNMK Hot Sheet
Price: $14.54 -2.15%
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade GNMK Now!
Canaccord Genuity maintains a 'Buy' on GenMark Diagnostics (NASDAQ: GNMK) price target of $12.00.
Analyst, Jeffrey Frelick, said, "We expect GNMK to report Q2/12 sales of $3.4M (+273% Y/Y), ahead of consensus of $3.1M; and EPS of $(0.26) vs. consensus of $(0.28)...In Q2, we look for GNMK to place 23 XT-8 instruments, vs. 22 in Q1/12 and 26 in Q4/11...We expect GNMK to report ~30% GM."
"GNMK has been executing on solid placements of its XT-8 instruments. Meanwhile, the company is developing its Nex-gen instrument platform (expected end of 2013). Until that time, we expect GNMK will add 2-4 more tests to its XT-8 platform and add sales reps to drive top-line growth."
For an analyst ratings summary and ratings history on GenMark Diagnostics click here. For more ratings news on GenMark Diagnostics click here.
Shares of GenMark Diagnostics closed at $5.37 yesterday, with a 52 week range of $3.63-$6.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jeffrey Frelick, said, "We expect GNMK to report Q2/12 sales of $3.4M (+273% Y/Y), ahead of consensus of $3.1M; and EPS of $(0.26) vs. consensus of $(0.28)...In Q2, we look for GNMK to place 23 XT-8 instruments, vs. 22 in Q1/12 and 26 in Q4/11...We expect GNMK to report ~30% GM."
"GNMK has been executing on solid placements of its XT-8 instruments. Meanwhile, the company is developing its Nex-gen instrument platform (expected end of 2013). Until that time, we expect GNMK will add 2-4 more tests to its XT-8 platform and add sales reps to drive top-line growth."
For an analyst ratings summary and ratings history on GenMark Diagnostics click here. For more ratings news on GenMark Diagnostics click here.
Shares of GenMark Diagnostics closed at $5.37 yesterday, with a 52 week range of $3.63-$6.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Goldman Sachs Upgrades Meritor (MTOR) to Buy
- UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
